MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Earnings Results, Beats Expectations By $0.21 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) issued its earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.21, Zacks reports.

MAIA Biotechnology Stock Down 10.9 %

NYSEAMERICAN:MAIA traded down $0.26 during midday trading on Thursday, reaching $2.13. 239,605 shares of the stock traded hands, compared to its average volume of 286,802. The stock has a market capitalization of $50.93 million, a price-to-earnings ratio of -1.54 and a beta of 0.32. MAIA Biotechnology has a 12-month low of $0.82 and a 12-month high of $5.99.

Insider Transactions at MAIA Biotechnology

In other news, Director Cristian Luput purchased 22,133 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average cost of $2.51 per share, with a total value of $55,553.83. Following the completion of the acquisition, the director now owns 389,483 shares of the company’s stock, valued at approximately $977,602.33. This represents a 6.03 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 36.98% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.